4/A: Director Nielsen Amends SpyGlass Pharma Ownership

Kirk G. Nielsen, a director of SpyGlass Pharma, Inc., filed an amended Form 4 to correct reported beneficial ownership following preferred stock conversion.

Summary

• Kirk G. Nielsen, a director of SpyGlass Pharma, Inc. (SGP), filed an amended Form 4 (Form 4/A) to correct previously reported beneficial ownership.
• The amendment clarifies the automatic conversion of various series of preferred stock (Series B, C-1, C-2, and D) into shares of the Issuer's common stock on a one-for-one basis.
• This conversion occurred prior to the closing of SpyGlass Pharma's initial public offering (IPO) without payment of additional consideration.
• Nielsen indirectly holds 3,310,619 shares of Common Stock through Vensana Capital I, L.P. (Vensana I).
• The amendment specifically corrects the number of shares reported in Column 5 of Table II of the original Form 4 filed on February 10, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing. It corrects a previous disclosure, which is a positive for data accuracy, but provides no new operational or financial insights.

Positives

• The filing provides increased accuracy and transparency regarding a director's beneficial ownership post-IPO.
• The conversion of preferred stock to common stock is a standard process preceding an IPO, simplifying the capital structure.

Future Outlook

No forward-looking statements or guidance are provided in this administrative filing.

Industry Context

StockSavvy.ai notes that Form 4/A filings are routine administrative updates, particularly common after significant corporate events like an IPO, to ensure accurate public disclosure of insider holdings. This filing reflects the standard process of preferred stock converting to common stock upon an IPO, a common mechanism for venture-backed companies going public.

Comparison to Industry Standards

• This filing is a standard post-IPO ownership disclosure and correction, aligning with typical regulatory compliance practices for directors of newly public companies.
• The one-for-one conversion of preferred stock to common stock prior to an IPO is a common mechanism observed across numerous companies transitioning from private to public ownership, such as those backed by venture capital firms like Vensana Capital.

Related Party Transactions

• Kirk G. Nielsen's indirect beneficial ownership of 3,310,619 shares of Common Stock is held by Vensana Capital I, L.P. (Vensana I).
• Nielsen is a managing director of Vensana Capital I GP, LLC (Vensana GP I), which is the general partner of Vensana I.
• Nielsen disclaims beneficial ownership of these securities except to the extent of his pecuniary interests therein.

Stakeholder Impact

• Shareholders: Provides accurate and updated information regarding a director's indirect holdings of common stock, enhancing transparency.
• Regulatory Authorities: Ensures compliance with Section 16(a) reporting requirements for insider transactions and beneficial ownership.

Key Dates

Recommendation

This filing is an administrative amendment to correct a director's beneficial ownership report following a preferred stock conversion related to the company's IPO. It does not contain new material information regarding the company's financial performance, strategic direction, or operational outlook that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate as existing investment theses remain unchanged based on this specific filing.

Keywords

SpyGlass Pharma, SGP, Kirk Nielsen, Form 4/A, Beneficial Ownership, Preferred Stock Conversion, IPO, Director, Vensana Capital